Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) ...

Roche's anti-CD20 antibody Gazyva has been on the market for more than a decade as a treatment for blood cancer, but could see a new lease of life if it gets FDA approval to treat kidney disease ...

Calquence plus Venclexta with or without Gazyva significantly improved progression-free survival in patients with untreated CLL. Among patients with previously untreated chronic lymphocytic leukemia ...

Bernstein analyst Justin Smith maintained a Buy rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF345.00.

It will also pay milestone payments of up to $1.875 billion to Gubra. FDA Accepts Roche’s Gazyva sBLA for Lupus Nephritis The FDA accepted a supplemental biologics license application (sBLA ...

The filing acceptance is based on positive results from the Phase III REGENCY study, which showed improved complete renal response (CRR) with Gazyva plus standard therapy compared Gazyva/Gazyvaro ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB’s Bimzelx achieved complete skin clearance.

Kelly Grosklags discusses how oncologists can guide patients in shared decision-making while managing expectations following a breast cancer diagnosis.